Yi-Ching Wang
Dr. Yi-Ching Wang received her PhD in Genetics from Michigan State University, USA. She returned to Taiwan to join the Department of Pharmacology at the College of Medicine, National Cheng Kung University, where she served as Professor until 2015, when she assumed her current position as Chair Professor at the same university.
Dr. Wang has a long-standing research interest in the molecular mechanisms of tumorigenesis, with a primary focus on lung cancer, which has since expanded to include esophageal, pancreatic, and colorectal cancers. Her group is currently investigating post-translational modifications of immune inhibitory receptors on T cells, as well as the functional role of Rab37, a small GTPase, in regulating exocytosis and its dysregulation in tumorigenesis and the tumor microenvironment. Her team is also actively engaged in the development of novel anti-cancer therapeutics and immunomodulatory antibodies.
Dr. Wang has published 146 SCI-indexed papers (i10-index: 127) in high-impact journals, including Cancer Research, Nature Communications, Science Advances, Cell Death & Differentiation, Journal of Clinical Investigation, and Nucleic Acids Research. She holds an H-index of 51. Her group has presented over 400 conference papers, authored four book chapters, and secured five Taiwan patents, three U.S. patents, and one PCT patent, with one technology successfully transferred.
Abstracts this author is presenting: